Clinuvel's Scenesse being trialled in HHD
10 February, 2014 by Dylan Bushell-EmblingAn Italian phase II trial of Clinuvel's (ASX:CUV) Scenesse in rare skin condition Hailey-Hailey Disease has commenced, with recruitment due to be complete by March.
TGA seeks experts for advisory roles
06 February, 2014The Therapeutic Goods Administration (TGA) is seeking expressions of interest from experts in relevant clinical or scientific fields who want to contribute to the regulation of therapeutic goods in Australia.
GI Dynamics gets expanded reimbursement in Germany
05 February, 2014 by Dylan Bushell-EmblingGermany's InEk has agreed to grant NUB Status 1 to GI Dynamics' (ASX:GID) EndoBarrier Therapy, allowing hospitals to negotiate for additional funding to cover the cost of procedures.
TGA clears three surgeons to use NovoSorb BTM
04 February, 2014 by Dylan Bushell-EmblingCalzada's (ASX:CZD) PolyNovo announced that three RAH surgeons have been authorised to prescribe its NovoSorb BTM dermal scaffold in free flap donor site repair surgery.
Novotech opens South African office
04 February, 2014 by Dylan Bushell-EmblingSydney-based CRO Novotech has established a dedicated presence in South Africa, its eleventh market, in response to a growing demand for clinical services in the nation.
Calling medical device and diagnostic companies with an interest in China
04 February, 2014AusBiotech is developing resources to support Australian medical device and diagnostics companies to engage with China. AusBiotech seeks your comments in a confidential quick survey to guide the development of the most suitable resources, in order to gauge what is needed.
Phase 1 of Admedus HSV-2 trial achieves primary endpoint
03 February, 2014Admedus (ASX:AHX) has announced interim study results on its phase 1 trial of a therapeutic vaccine for herpes simplex virus (HSV-2).
Mesoblast's MPCs reduce back pain in phase II trial
30 January, 2014 by Dylan Bushell-EmblingPatients with low back pain from early disc degeneration treated with Mesoblast (ASX:MSB) MPCs during a phase II trial reported reduced back pain and required fewer pain drugs compared to controls.
Medtech event of the year open for registration
30 January, 2014The annual AusMedtech national conference will again be held in Melbourne, from 1-2 April at the Hilton on the Park. The flagship medical technology event of the year has just confirmed Mick Farrell, CEO of ResMed, to speak on day one.
Calzada scores licence deal for AOD9604
28 January, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) subsidiary Metabolic has secured the first of what it hopes will be a number of licensing agreements with Australian compounding pharmacies for its peptide drug AOD9604.
IDT Australia weighing acquiring HRT product
28 January, 2014 by Dylan Bushell-EmblingIDT Australia (ASX:IDT) is evaluating acquiring Perrigo's US ANDA filing for a synthetic oestrogen product, as it seeks to expand its specialty generic drug portfolio.
Annual CEO industry survey to check the 'pulse' of the Australian industry
28 January, 2014AusBiotech calls on industry leaders (CEOs and MDs) to respond to the annual Biotechnology Industry Position Survey 2014 in order to contribute to the annual snapshot and build the advocacy platform for the year to come.
Cochlear facing $150m penalty from patent case
24 January, 2014 by Dylan Bushell-EmblingA US jury has found Cochlear (ASX:COH) liable of patent infringement and awarded damages of US$131.2m, but the company has vowed to appeal.
iSonea products recognised at CES
23 January, 2014 by Dylan Bushell-EmblingiSonea (ASX:ISN) has picked up a Tech Podcast Network award for its asthma symptom monitoring tools AirSonea and AsthmaSense Prime.
Immuron to raise $9.6m in rights issue
23 January, 2014 by Dylan Bushell-EmblingImmuron (ASX:IMC) has commenced a $9.6m capital raising, for purposes including raising funds for upcoming phase IIb trial of IMM-124E in NASH.
